The practical value of applying chemical biliary duct embolization to chemical hepatectomy for treatment of hepatolithiasis
- PMID: 15936771
- DOI: 10.1016/j.jss.2005.02.029
The practical value of applying chemical biliary duct embolization to chemical hepatectomy for treatment of hepatolithiasis
Abstract
Background: The high recurrence rate of hepatolithiasis, together with the high operative risk of hepatectomy for specifically located stones, has not been effectively settled until now. Thus, the aim of this study was to investigate the feasibility and effectiveness of using chemical biliary duct embolization (CBDE) to achieve chemical hepatectomy in a rabbit model of hepatolithiasis.
Materials and methods: The animal model of hepatolithiasis was established using the methods of obstruction plus infection. Seven days later, the left hepatic ducts were embolized using phenol plus cyanoacrylate or absolute ethanol plus cyanoacrylate. Subsequently, the influence of CBDE on bile duct, liver, and stone formation was analyzed by histology, RT-PCR for procollagen, biochemistry, and enzymatic histochemistry for beta-glucuronidase (beta-G).
Results: CBDE resulted in the entire ablation of the diseased biliary duct mucosa and the complete occlusion of the diseased biliary duct lumen, thus effectively eradicating chronic proliferative cholangitis and preventing stone formation. More importantly, CBDE also resulted in the complete fibrosis and "self-cut" in the periphery of the embolized lobe, thus achieving chemical hepatectomy. Also of note, the embolized lobe exhibited a much lower level of endogenous beta-G than the nonembolized lobe, indicating an inhibitory effect of CBDE on beta-G. Besides, the mRNA level of procollagen I in the embolized bile duct wall of phenol embolization group was significantly higher than the ethanol embolization group.
Conclusion: Chemical biliary duct embolization, especially using phenol plus cyanoacrylate, may prevent the recurrence of intrahepatic stone and concurrently achieve the effect of chemical hepatectomy.
Similar articles
-
Applying chemical bile duct embolization to achieve chemical hepatectomy in hepatolithiasis: a further experimental study.J Surg Res. 2014 Mar;187(1):113-21. doi: 10.1016/j.jss.2013.10.053. Epub 2013 Nov 1. J Surg Res. 2014. PMID: 24290428
-
Preliminary study of chemical bile duct embolization to treat hepatolithiasis in rabbits.J Gastroenterol Hepatol. 2006 Jun;21(6):994-8. doi: 10.1111/j.1440-1746.2006.04265.x. J Gastroenterol Hepatol. 2006. PMID: 16724984
-
Effectiveness of chemical biliary duct embolization for chemical hepatectomy.J Gastroenterol Hepatol. 2006 May;21(5):880-6. doi: 10.1111/j.1440-1746.2005.04090.x. J Gastroenterol Hepatol. 2006. PMID: 16704540
-
Clinical prospect of applying the chemical bile duct embolization to achieve a chemical hepatectomy in the treatment of highly selected hepatolithiasis.Surg Laparosc Endosc Percutan Tech. 2009 Jun;19(3):183-7; discussion 187-9. doi: 10.1097/SLE.0b013e3181a81de5. Surg Laparosc Endosc Percutan Tech. 2009. PMID: 19542840 Review.
-
Modern imaging in the evaluation of hepatolithiasis.Hepatogastroenterology. 1997 Mar-Apr;44(14):358-69. Hepatogastroenterology. 1997. PMID: 9164502 Review.
Cited by
-
Significance of controlling chronic proliferative cholangitis in the treatment of hepatolithiasis.World J Surg. 2009 Oct;33(10):2155-60. doi: 10.1007/s00268-009-0154-8. World J Surg. 2009. PMID: 19641953 Review.
-
Surgical treatment of complicated hepatolithiasis using the ultrasound-guided fiberoptic choledochoscope.Surg Endosc. 2011 Feb;25(2):497-502. doi: 10.1007/s00464-010-1200-1. Epub 2010 Jul 8. Surg Endosc. 2011. PMID: 20614140
-
Laparoscopic hepatectomy for hepatolithiasis: a feasibility and safety study in 29 patients.Surg Endosc. 2007 Jul;21(7):1074-8. doi: 10.1007/s00464-007-9306-9. Epub 2007 May 22. Surg Endosc. 2007. PMID: 17516119
-
Recurrent pyogenic cholangitis: disease characteristics and patterns of recurrence.ISRN Surg. 2013 May 25;2013:536081. doi: 10.1155/2013/536081. Print 2013. ISRN Surg. 2013. PMID: 23762626 Free PMC article.
-
EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR.Int J Mol Med. 2019 Jul;44(1):79-88. doi: 10.3892/ijmm.2019.4190. Epub 2019 May 9. Int J Mol Med. 2019. PMID: 31115490 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical